Tag Archives: BIO Events

My First Blog Entry: An Enlivened Biotech Industry and BIO International Convention

Scott Whitaker

While Washington, DC struggles with yet another round of cold temperatures, inside the halls of BIO, we have turned the heat up and are working hard to make many exciting changes to the 2014 BIO International Convention in SUNNY San Diego. It is more than just California dreaming – our team has been breaking a sweat responding to all of the early registrations for this year’s event (it is how they get into convention shape). Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Find Your Next Asia Partnership in Tokyo at BIO Asia

Asia2013_115x76_Thumbnail copy

On April 8-9, 2014, the BIO Asia International Conference will enter its eleventh year. This year, biopharma industry leaders will convene at the Grand Hyatt in Tokyo, Japan to make the cross border deals that will advance collaboration between Asia and the West. This event has become the premier customized partnering event for Western and Asian biopharma executives. According to JP Morgan healthcare specialist Scott Braunstein, Japan has become one of the most critical markets for pharma Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , ,

The Economist – Biotechnology: Fever Rising

The-Economist-115x76

After speaking with several attendees and speakers at last week’s BIO CEO & Investor Conference, the Economist featured an article this week about the strong performance of biotech equities recently: AS INVESTORS and executives crammed into a New York ballroom for a conference held this week by the Biotechnology Industry Organisation, the mood was jittery. The previous week eight biotech firms had launched initial public offerings in America, together raising more than $500m. In a discussion Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , ,

Business Roundtable: The Reimbursement Landscape under ACA

Capture

As the Affordable Care Act is implemented, reimbursement for life-saving and life-enhancing drugs is one of the most pressing issues facing healthcare stakeholders and decision makers, including patients, payers, providers, and innovative drug developers. BIO hosted a business roundtable discussion on this timely topic yesterday at our 16th Annual BIO CEO & Investor Conference. Moderated by Real Endpoint’s Roger Longman, panelists represented a variety of perspectives: Peter Bach, MD, MAPP, Attending Physician, Memorial Sloan-Kettering Cancer Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

#BIOCEO14: An Optimistic Outlook for 2014

Panel

The 16th Annual BIO CEO & Investor Conference​ concluded with a lively Closing Plenary Session examining the current capital market for IPOs, where the industry has been and where it’s headed in 2014. The panel unanimously agreed: 2013 was the year of the IPO. In total, 56 healthcare companies priced an IPO; 43 of these were biotech companies. Last year was the strongest IPO year since 2000 and the second strongest in history with over $10 Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,